Translational Medicine for Prevention, Diagnosis, and Treatment of Liver Disease

VIEWS - 136 (Abstract) 46 (PDF)
Cheng Jin, Ling Bai, Shuangquan Wang


Translational medicine is a new concept emerging in the field of international biomedicine in recent years. Translational medicine revolves around the transformation of basic research findings into clinical application. Translational medicine has made a huge progress in the prevention, diagnosis, and treatment of liver diseases, especially diffuse diseases and liver cancer. This paper reviews the development of translational medical research of liver disease, as well as discusses the advancement of liver surgery, molecular targeted therapy, immunotherapy, stem cell therapy, genomics, and hepatitis B vaccine.


Translational medicine, Liver disease, Diagnosis, Treatment

Full Text:

Download PDF


Yamamoto M, Ariizumi SI, 2018, Glissonean Pedicle Approach in Liver Surgery. Ann Gastroenterol Surg, 2(2):124-28. DOI: 10.1002/ags3.12062.

Qian NS, Liao YH, Cai SW, et al., 2013, Comprehensive Application of Modern Technologies in Precise Liver Resection. Hepatobiliary Pancreat Dis Int, 12(3):244-50. DOI: 10.1016/s1499-3872(13)60040-5.

Couinaud C, 1992, The Anatomy of the Liver. Ann Ital Chir, 63:693-7.

Chen MS, Zhang YJ, Xu L, 2009, Research Progress of Molecular-targeted Agents in Hepatocellular Carcinoma. Chin J Dig Srurg, 8(2):96-8.

Wilhelm S, Carter C, Lynch M, et al., 2006, Discovery and Development of Sorafenib: A Multikinase Inhibitor for Treating Cancer. Nat Rev Drug Discov, 5:835-44. DOI: 10.1038/nrd2130.

Llovet JM, Ricci S, Mazzaferro V, et al., 2008, Sorafenib in Advanced Hepatocellular Carcinoma. N Engl J Med, 359:378-90.

Jackson R, Psarelli EE, Berhane S, et al., 2017, Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials. J Clin Oncol, 35(6622-8. DOI: 10.1200/jco.2016.69.5197.

Adhoute X, Pénaranda G, Raoul JL, et al., 2019, Prognostication of HCC Under Sorafenib: Is it Always Possible? Liver Int. DOI 10.1111/liv.14294.

Chen F, Fang Y, Zhao R, et al., 2019, Evolution in Medicinal Chemistry of Sorafenib Derivatives for Hepatocellular Carcinoma. Eur J Med Chem, 179:916-35.

Xu W, Liu K, Chen M, et al., 2019, Immunotherapy for Hepatocellular Carcinoma: Recent Advances and Future Perspectives. Ther Adv Med Oncol, 11:1758835919862692.

El Dika I, Khalil DN, Abou-Alfa GK, 2019, Immune Checkpoint Inhibitors for Hepatocellular Carcinoma. Cancer, 125(19):3312-9. DOI: 10.1002/cncr.32076.

Havel JJ, Chowell D, Chan TA, 2019, The Evolving Landscape of Biomarkers for Checkpoint Inhibitor Immunotherapy. Nat Rev Cancer, 19(3):133-50. DOI: 10.1038/s41568-019-0116-x.

Okazaki T, Honjo T, 2007, PD-1 and PD-1 Ligands: From Discovery to Clinical Application. Int Immunol, 19(7):813- 24. DOI: 10.1093/intimm/dxm057.

Finkelmeier F, Waidmann O, Trojan J, 2018, Nivolumab for the Treatment of Hepatocellular Carcinoma. Expert Rev Anticancer Ther, 18(12):1169-75. DOI: 10.1080/14737140.2018.1535315.

Kudo M, 2016, Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update. Liver Cancer, 6(1):1-12. DOI: 10.1159/000449342.

Obeid JM, Kunk PR, Zaydfudim VM, et al., 2018, Immunotherapy for Hepatocellular Carcinoma Patients: Is it Ready for Prime Time? Cancer Immunol Immunother, 67(2):161-74. DOI: 10.1007/s00262-017-2082-z.

Cheng H, Sun G, Chen H, et al., 2019, Trends in the Treatment of Advanced Hepatocellular Carcinoma: Immune Checkpoint Blockade Immunotherapy and Related Combination Therapies. Am J Cancer Res, 9(8):1536-45.

Zhou C, Liu JC, Shi Q, et al., 2019, Current Situation and Research Advances of Molecular Targeted Drugs and Immunosuppressive Therapy for Hepatocellular Carcinoma. Chin J Inter Rad (Electronic Edition), 7(3):243-50.

Navarro-Alvarez N, Soto-Gutierrez A, Kobayashi N, 2009, Stem Cell Research and Therapy for Liver Disease. Curr Stem Cell Res Ther, 4:141-6. DOI: 10.2174/157488809788167418.

Bartlett DC, Newsome PN, 2015, Hepatocyte Cell Therapy in Liver Disease. Expert Rev Gastroenterol Hepatol, 9(10):1261-72.

Nicolas CT, Wang Y, Nyberg SL, 2016, Cell Therapy in Chronic Liver Disease. Curr Opin Gastroenterol, 32(3):189 94.

Sokal EM, 2011, From Hepatocytes to Stem and Progenitor Cells for Liver Regenerative Medicine: Advances and Clinical Perspectives. Cell Prolif, 44(1):39-43. DOI: 10.1111/j.1365-2184.2010.00730.x.

Visvader JE, 2011, Cells of Origin in Cancer. Nature, 469(7330):314-22.

Batlle E, Clevers H, 2017, Cancer Stem Cells Revisited. Nat Med, 23(10):1124-34. DOI: 10.1038/nm.4409.

Duan X, Wang Y, He J, et al., 2017, Progress of the Application of Stem Cell Therapy for End-stage Liver Disease. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 42(4):457 62.

Kisseleva T, Gigante E, Brenner DA, 2010, Recent Advances in Liver Stem Cell Therapy. Curr Opin Gastroenterol, 26(4):395-402. DOI: 10.1097/mog.0b013e32833a6bec.

Alwahsh SM, Rashidi H, Hay DC, 2018, Liver Cell Therapy: Is this the End of the Beginning? Cell Mol Life Sci, 75(8):1307-24. DOI: 10.1007/s00018-017-2713-8.

Dalgetty DM, Medine CN, Iredale JP, et al., 2009, Progress and Future Challenges in Stem Cell-derived Liver Technologies. Am J Physiol Gastrointest Liver Physiol, 297(2):G241-8. DOI: 10.1152/ajpgi.00138.2009.

Bai L, Jin C, 2019, Nanomedicine and Liver Cancer Stem Cells. Gastroenterol Hepatol Lett, 1(1):1-5.

Sun LY, Li XY, Sun ZW, 2015, Progress of Epigenetics and its Therapeutic Application in Hepatocellular Carcinoma. Hereditas, 37(6):517-27.

Dhanasekaran R, Nault JC, Roberts LR, et al., 2019, Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy. Gastroenterology, 156(2):492-509. DOI: 10.1053/j.gastro.2018.11.001.

Shibata T, Arai Y, Totoki Y, 2018, Molecular Genomic Landscapes of Hepatobiliary Cancer. Cancer Sci, 109(5):1282-91. DOI: 10.1111/cas.13582.

Yim SY, Lee JS, 2019, Genomic Perspective on Mouse Liver Cancer Models. Cancers (Basel), 11(11):E1648.

Setshedi M, Andersson M, Kgatle MM, et al., 2018, Molecular and Cellular Oncogenic Mechanisms in Hepatocellular Carcinoma. S Afr Med J, 108(8b):41-6.

Toh TB, Lim JJ, Chow EK, 2019, Epigenetics of Hepatocellular Carcinoma. Clin Transl Med, 8(1):13.

Huang W, Skanderup AJ, Lee CG, 2018, Advances in Genomic Hepatocellular Carcinoma Research. Gigascience, 7(11):135.

Hou J, Liu Z, Gu F, 2005, Epidemiology and Prevention of Hepatitis B Virus Infection. Int J Med Sci, 2:50-7.

Das S, Ramakrishnan K, Behera SK, et al., 2019, Hepatitis B Vaccine and Immunoglobulin: Key Concepts. J Clin Transl Hepatol, 7(2):165-71.

Fan W, Chen XF, Shen C, et al., 2016, Hepatitis B Vaccine Response in Obesity: A Meta-analysis. Vaccine, 34(40):4835-41. DOI: 10.1016/j.vaccine.2016.08.027.

Cui F, Shen L, Li L, et al., 2017, Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China. Emerg Infect Dis, 23(5):765-72. DOI: 10.3201/ eid2305.161477.

Luo Z, Li L, Ruan B, 2012, Impact of the Implementation of a Vaccination Strategy on Hepatitis B Virus Infections in China Over a 20-year Period. Int J Infect Dis, 16(2):e82-8. DOI: 10.1016/j.ijid.2011.10.009.

Liang ZL, 2013, Progress on the Research and Application of Hepatitis B Vaccine in China. Chin J Microbiol Immunol, 30(1):11-4.

Guan J, Chen J, 2011, Translational Research and its Effects on Medicine in China. Chin Med J (Engl), 124(19):3170-5.



  • There are currently no refbacks.

Copyright (c) 2019 Jin, et al.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Recent Articles | About Journal | For Author | Fees | About Whioce

Copyright © Whioce Publishing Pte Ltd. All Rights Reserved.